DE69738811D1 - Oberflächenantigene aus Säugern - Google Patents

Oberflächenantigene aus Säugern

Info

Publication number
DE69738811D1
DE69738811D1 DE69738811T DE69738811T DE69738811D1 DE 69738811 D1 DE69738811 D1 DE 69738811D1 DE 69738811 T DE69738811 T DE 69738811T DE 69738811 T DE69738811 T DE 69738811T DE 69738811 D1 DE69738811 D1 DE 69738811D1
Authority
DE
Germany
Prior art keywords
mammals
surface antigens
reagents
antigen
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69738811T
Other languages
English (en)
Inventor
Daniel M Gorman
Jeanine D Mattson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21867133&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69738811(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Priority to DE122010000046C priority Critical patent/DE122010000046I1/de
Application granted granted Critical
Publication of DE69738811D1 publication Critical patent/DE69738811D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69738811T 1996-12-13 1997-12-12 Oberflächenantigene aus Säugern Expired - Lifetime DE69738811D1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE122010000046C DE122010000046I1 (de) 1996-12-13 1997-12-12 Oberflächenantigene aus Säugern

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3284696P 1996-12-13 1996-12-13

Publications (1)

Publication Number Publication Date
DE69738811D1 true DE69738811D1 (de) 2008-08-14

Family

ID=21867133

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69738811T Expired - Lifetime DE69738811D1 (de) 1996-12-13 1997-12-12 Oberflächenantigene aus Säugern
DE122010000046C Pending DE122010000046I1 (de) 1996-12-13 1997-12-12 Oberflächenantigene aus Säugern

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE122010000046C Pending DE122010000046I1 (de) 1996-12-13 1997-12-12 Oberflächenantigene aus Säugern

Country Status (15)

Country Link
US (5) US6242586B1 (de)
EP (5) EP1114864B9 (de)
JP (6) JP2001506991A (de)
CN (1) CN1245534A (de)
AT (1) ATE399861T1 (de)
AU (1) AU5697098A (de)
BR (1) BR9714401A (de)
CA (1) CA2274801C (de)
DE (2) DE69738811D1 (de)
DK (1) DK1114864T4 (de)
ES (1) ES2305009T5 (de)
HK (1) HK1034743A1 (de)
LU (1) LU91756I2 (de)
PT (1) PT1114864E (de)
WO (1) WO1998025958A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US7632922B1 (en) * 1995-12-22 2009-12-15 Amgen, Inc. Osteoprotegerin
EP1114864B9 (de) * 1996-12-13 2013-05-08 Schering Corporation Oberflächenantigene aus Säugern
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
EP2371962A3 (de) 1996-12-23 2011-12-21 Immunex Corporation Ligand für Rezeptor Aktivator von NF-KAPPA B, Ligand ist Mitglied der TNF Superfamilie
RU2238949C2 (ru) * 1997-04-15 2004-10-27 Санкио Компани Лимитед Белок, специфически связывающийся с ингибирующим остеокластогенез фактором (ocif) (варианты), днк его кодирующая (варианты), днк в качестве зонда (варианты), способ получения белка (варианты), способ скрининга вещества (варианты), антитело (варианты), способ получения поликлонального антитела, гибридома (варианты), способ получения моноклонального антитела, способ измерения ocif-связывающего белка, фармацевтическая композиция (варианты) и лекарственное средство (варианты)
AU2008200700C1 (en) * 1997-04-15 2013-04-04 Daiichi Sankyo Co., Ltd Novel Protein and Process for Producing The Same
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
RO128635A2 (ro) * 1997-04-16 2013-07-30 Amgen Inc. Anticorp sau fragment al acestuia care se leagă la opgbp şi utilizarea acestuia, utilizarea unei forme solubile de odar, şi metodă de identificare a unui compus care descreşte activitatea opgbp
AU2011202547B2 (en) * 1997-04-16 2014-08-28 Amgen Inc. Osteoprotegerin binding proteins and receptors
US6084926A (en) * 1997-12-08 2000-07-04 Ericsson Inc. Method and system for demodulating radio signals
US7063960B2 (en) 1997-12-12 2006-06-20 The Rockefeller University Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
CA2328140C (en) * 1998-05-14 2012-03-13 Immunex Corporation Method of inhibiting osteoclast activity
DK1114166T3 (da) * 1998-09-15 2005-08-01 Pharmexa As Fremgangsmåde til nedregulering af osteoprotegerinligandaktivitet
AU754971B2 (en) * 1998-09-15 2002-11-28 Pharmexa A/S Method for down-regulating osteoprotegerin ligand activity
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
EP1257648B2 (de) † 2000-02-23 2016-09-14 Amgen Inc. Antagonistische selektive bindungsagenzien des osteoprotegerin-bindungsproteins
DE01973455T1 (de) * 2000-09-22 2004-04-22 Immunex Corp., Seattle Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b
US7128911B2 (en) * 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
JP4761710B2 (ja) 2002-04-05 2011-08-31 アムジェン インコーポレイテッド 選択的ｏｐｇｌ経路インヒビターとしてのヒト抗ｏｐｇｌ中和抗体
US7462700B2 (en) * 2002-12-10 2008-12-09 Schering-Plough Animal Health Corporation Canine RANKL and methods for preparing and using the same
EP1750761A1 (de) * 2004-06-02 2007-02-14 Cytos Biotechnology AG Medizinische verwendungen von trägerkonjugaten nicht-humaner tnf-peptide
US7582910B2 (en) * 2005-02-28 2009-09-01 The Regents Of The University Of California High efficiency light emitting diode (LED) with optimized photonic crystal extractor

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2031216A1 (de) 1969-06-19 1971-01-14 Citizen Watch Co Ltd , Tokio Tag und Datum Stellvorrichtung fur Uhren mit Kalender
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
ATE64618T1 (de) 1982-03-15 1991-07-15 Schering Corp Hybride dns, damit hergestellte bindungszusammensetzung und verfahren dafuer.
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4859609A (en) 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
ES2118372T3 (es) 1992-11-17 1998-09-16 Icos Corp Nuevos receptores siete transmembrana v28.
IL117175A (en) * 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
WO1996031625A1 (en) * 1995-04-07 1996-10-10 Cytogen Corporation Polypeptides having a functional domain of interest and methods of identifying and using same
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6111090A (en) * 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
EP1114864B9 (de) * 1996-12-13 2013-05-08 Schering Corporation Oberflächenantigene aus Säugern
EP2371962A3 (de) * 1996-12-23 2011-12-21 Immunex Corporation Ligand für Rezeptor Aktivator von NF-KAPPA B, Ligand ist Mitglied der TNF Superfamilie
US6271349B1 (en) * 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
RU2238949C2 (ru) * 1997-04-15 2004-10-27 Санкио Компани Лимитед Белок, специфически связывающийся с ингибирующим остеокластогенез фактором (ocif) (варианты), днк его кодирующая (варианты), днк в качестве зонда (варианты), способ получения белка (варианты), способ скрининга вещества (варианты), антитело (варианты), способ получения поликлонального антитела, гибридома (варианты), способ получения моноклонального антитела, способ измерения ocif-связывающего белка, фармацевтическая композиция (варианты) и лекарственное средство (варианты)
US5843678A (en) 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
RO128635A2 (ro) * 1997-04-16 2013-07-30 Amgen Inc. Anticorp sau fragment al acestuia care se leagă la opgbp şi utilizarea acestuia, utilizarea unei forme solubile de odar, şi metodă de identificare a unui compus care descreşte activitatea opgbp
CA2328140C (en) * 1998-05-14 2012-03-13 Immunex Corporation Method of inhibiting osteoclast activity

Also Published As

Publication number Publication date
ES2305009T5 (es) 2012-11-15
EP1114864A3 (de) 2001-10-10
EP0948530A2 (de) 1999-10-13
EP1995317A1 (de) 2008-11-26
JP2010172336A (ja) 2010-08-12
EP1114864A2 (de) 2001-07-11
EP1114864B2 (de) 2012-07-25
CA2274801A1 (en) 1998-06-18
JP2009254381A (ja) 2009-11-05
US20030144480A1 (en) 2003-07-31
PT1114864E (pt) 2008-10-08
JP2010119397A (ja) 2010-06-03
US20060025572A1 (en) 2006-02-02
US6525180B1 (en) 2003-02-25
ATE399861T1 (de) 2008-07-15
US6242586B1 (en) 2001-06-05
EP1995318A1 (de) 2008-11-26
DK1114864T4 (da) 2012-09-03
BR9714401A (pt) 2000-04-18
EP1803816A3 (de) 2007-09-26
JP2008143906A (ja) 2008-06-26
EP1995317B1 (de) 2014-11-05
JP2013074899A (ja) 2013-04-25
DE122010000046I1 (de) 2011-05-05
US20090092597A1 (en) 2009-04-09
CA2274801C (en) 2014-02-04
US7063841B2 (en) 2006-06-20
WO1998025958A2 (en) 1998-06-18
JP2001506991A (ja) 2001-05-29
EP1114864B1 (de) 2008-07-02
DK1114864T3 (da) 2008-10-06
LU91756I2 (fr) 2011-01-24
CN1245534A (zh) 2000-02-23
HK1034743A1 (en) 2001-11-02
EP1114864B9 (de) 2013-05-08
AU5697098A (en) 1998-07-03
ES2305009T3 (es) 2008-11-01
WO1998025958A3 (en) 1998-07-30
EP1803816A2 (de) 2007-07-04

Similar Documents

Publication Publication Date Title
DE69738749D1 (de) Zelloberflächen-antigen aus säugetieren und verwandte reagenzien
DE69738811D1 (de) Oberflächenantigene aus Säugern
WO1998027114A3 (en) Mammalian cell surface antigens; related reagents
MY157028A (en) Mammalian cytokine, related reagents
WO1995018826A3 (en) Purified primate ctla-8 antigens and related reagents
WO1997021812A3 (en) Mammalian chemokine ccf8 and chemokine receptor cckr3
WO2000042188A3 (en) Interleukin-17 related mammalian cytokines. polynucleotides encoding them. uses
ATE456656T1 (de) Isolierte gene aus säuger monozyten und betreffende reagentien
ATE341626T1 (de) Membranproteine aus säugetierzellen; verwandte reagentien
WO1998011226A3 (en) Mammalian chemokines, related reagents
ATE389018T1 (de) Cx3c chemokin-gene von säugetieren
WO1998039421A3 (en) Mammalian proteinases; oxidoreductases; gtp binding proteins; related reagents
WO1998032858A3 (en) Mammalian chemokines; receptors; reagents; uses
ATE265533T1 (de) Saeugetierchemokine
ATE294237T1 (de) S?ugetier thymokingene
EP0997476A3 (de) Antikörper gegen ein Antigen auf Langerhans Zellen in Säugetieren und deren Verwendungen
WO1998031810A3 (en) Mammalian chemokines; receptors; reagents; uses
WO1999047673A3 (en) Isolated mammalian membrane protein genes and related reagents
EP1867720A3 (de) Für Zelloberflächenantigene von Säugetieren kodierende gereinigte Gene; Proteine und Antikörper
WO2000034335A3 (en) 'death domain' containing receptors
WO1999019491A3 (en) Human dnax interleukin-40 (dil-40)
ECSP982583A (es) Genes aislados de proteinas de membranas de mamiferos reactivos relacionados

Legal Events

Date Code Title Description
8363 Opposition against the patent